• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.

Science 15. November 2022
ShareTwitterFacebookXingLinkedin
First published in British Journal of Clinical Pharmacology on 2013 Dec.Br J Clin Pharmacol. 2013 Dec;76(6):888-96. doi: 10.1111/bcp.12129. Authors: Brossard...
Read Article

Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

Science 10. November 2022
ShareTwitterFacebookXingLinkedin
First published in European Journal of Clinical Pharmacology on 2011 Oct.Eur J Clin Pharmacol. 2011 Oct;67(10):977-84. doi: 10.1007/s00228-011-1043-2. Authors: Sidharta...
Read Article

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.

Science 26. September 2022
ShareTwitterFacebookXingLinkedin

This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious Pseudomonas aeruginosa infections.

Read Article
QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • PATIENT TRIALS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
  • www.probandeninfo.de
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Career
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2023 CRS. Experts. Early Phase. All rights reserved.